Brac'

neutrophil activating protein-2 (NAP-2) [NAP-2].

20. (Amended) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of a [chemokine peptide 3] peptide of a chemokine, a variant thereof, a derivative thereof, or a combination thereof, wherein the peptide comprises no more than 30 amino acid residues, wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, wherein the three contiguous residues correspond to residues Trp-Val-Gln or Lys-Gln-Lys in human MCP-1, and wherein the peptide inhibits the response induced by the corresponding native chemokine[, a chemokine peptide 2, a variant thereof, a derivative thereof, a compound of formula (IV), a compound of formula (V), a compound of formula (VI), or a combination thereof].

B3

22. (Amended) A method to modulate the chemokine-induced activity of hematopoietic cells at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a [chemokine peptide 3] peptide of a chemokine, a variant thereof, a derivative thereof, or a combination thereof, wherein the peptide comprises no more than 30 amino acid residues, wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, wherein the three contiguous residues correspond to residues Trp-Val-Gln or Lys-Gln-Lys in human MCP-1, and wherein the peptide inhibits the response induced by the corresponding native chemokine, [a chemokine peptide 2, a variant thereof, a derivative thereof, a compound of formula (IV), a compound of formula (V), a compound of formula (VI), or a combination thereof,] wherein the dosage form is linked to a site targeting moiety.

B4

34. (Amended) A method to [increase or enhance] alter hematopoietic cell-associated activity at a tumor site, comprising: administering an effective amount of a [chemokine peptide

B5

3] peptide of a chemokine, a variant thereof, a derivative thereof, or a combination thereof, wherein the peptide comprises no more than 30 amino acid residues, and wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, wherein the three contiguous residues correspond to residues Trp-Val-Gln or Lys-Gln-Lys in human MCP-1[, a chemokine peptide 2, a variant thereof, a derivative thereof, a compound of formula (IV), a compound of formula (V), a compound of formula (VI), or a combination thereof].

Please add the following new claims:

52. (New) The method of claim 17, 20, 22 or 34, wherein the peptide of a chemokine is a peptide of a CC chemokine.

53. (New) The method of claim 52, wherein the CC chemokine is monocyte chemotactic protein-1 (MCP-1), regulated on activation, normal T expressed and secreted protein (RANTES), monocyte chemotactic protein-2 (MCP-2), monocyte chemotactic protein-3 (MCP-3), monocyte chemotactic protein-4 (MCP-4), eotaxin, macrophage inflammatory protein-1α (MIP1α), MIP1β, liver and activation regulated chemokine (LARC), I309, hemofiltrate CC-chemokine -1 (HCC-1), thymus and activation regulated chemokine (TARC) or chemokine beta 8 (Ckβ8).

54. (New) The method of claim 17, 20, 22 or 34, wherein the peptide of a chemokine is a peptide of a CXC chemokine.

55. (New) The method of claim 20, 22 or 34, wherein the CXC chemokine is interleukin 8 (IL-8), interferon inducible protein 10 (IP-10), platelet factor-4 (PF-4), stromal cell-derived factor-1 (SDF-1α), neutrophil activating protein-2 (NAP-2), growth regulated oncogene alpha (GROα), GROβ, GROγ or epithelial neutrophil activating peptide-78 (ENA78).

56. (New) The method of claim 17, wherein the CXC chemokine is interferon inducible protein 10 (IP-10), platelet factor-4 (PF-4), stromal cell-derived factor-1 (SDF-1α), growth regulated oncogene alpha (GROα), GROβ, GROγ or epithelial neutrophil activating peptide-78

(ENA78).

57. (New) The method of claim 56, wherein the variant peptide is Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

58. (New) The method of claim 17, 20, 22 or 34, wherein the peptide of a chemokine comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

59. (New) The method of claim 17, 20, 22, or 34, wherein the peptide of a chemokine is a cyclic reverse D sequence (CRD) derivative or a variant thereof.

60. (New) The method of claim 59, wherein the CRD derivative is CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

61. (New) The method of claim 17, 20, 22, or 34, wherein the variant peptide is a variant peptide of peptide 3(3-12)[MCP-1].

62. (New) The method of claim 17, wherein the indication is atherosclerosis, multiple sclerosis, hypertension, asthma, allergy, psoriasis, rheumatoid arthritis, osteoporosis, stroke, acute ischemia, or organ transplant rejection.

Remarks

Reconsideration and withdrawal of the rejections of the claims, in view of the amendments and remarks presented herein, is respectfully requested. Claims 17, 20, 22, and 34 are amended, claims 1-16, 18-19, 23, 29-30, 36-39, 46-47, and 51 are canceled, and claims 52-62 are added. Claims 17, 20-22, 24-28, 31-35, 40-45, 48-50, and 52-62 are pending. The amendments to the claims are intended to clarify Applicant's invention and are not intended to limit the equivalents to which any claim is entitled.